Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by QRG Capital Management Inc.

QRG Capital Management Inc. lifted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 16.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 329,644 shares of the company’s stock after purchasing an additional 47,490 shares during the quarter. QRG Capital Management Inc.’s holdings in Takeda Pharmaceutical were worth $4,364,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Public Employees Retirement System of Ohio purchased a new position in Takeda Pharmaceutical during the 3rd quarter worth approximately $601,000. Verition Fund Management LLC purchased a new position in shares of Takeda Pharmaceutical during the third quarter worth $1,533,000. HighTower Advisors LLC lifted its position in Takeda Pharmaceutical by 199.5% during the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock valued at $1,744,000 after purchasing an additional 81,653 shares during the period. XTX Topco Ltd purchased a new stake in Takeda Pharmaceutical in the third quarter valued at $957,000. Finally, Versant Capital Management Inc acquired a new stake in Takeda Pharmaceutical during the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $14.40 on Friday. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The firm has a market capitalization of $45.82 billion, a P/E ratio of 36.00, a PEG ratio of 0.24 and a beta of 0.51. The stock has a 50-day simple moving average of $13.41 and a two-hundred day simple moving average of $13.89.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.